Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Table 5 Resource use, utilities and work loss per 3-month period by number of headache days per month

Health State	GP/A&E Visits	Avg. number of days absent	Utilities (EQ-VAS)
Health State	GP/A&E Visits	Avg. number of days absent	Mean	SD
0–3 headache days	0.82	1.44	0.776	0.144
4–9 headache days	1.24	3.52	0.702	0.167
10–14 headache days	1.34	8.41	0.631	0.180
15–19 headache days	1.49	6.81	0.615	0.181
20–23 headache days	2.41	19.40	0.474	0.217
24+ headache days	2.49	28.22	0.468	0.231

ISSN: 1129-2377